menu
    • menu
    [{"orgOrder":0,"company":"TrippBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"TD213","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"TrippBio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TrippBio \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"TrippBio \/ Undisclosed"},{"orgOrder":0,"company":"TrippBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"TD213","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"TrippBio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TrippBio \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"TrippBio \/ Undisclosed"},{"orgOrder":0,"company":"TrippBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Probenecid","moa":"Solute carrier family 22 member 6 | Solute carrier family 22 member 8 | Solute carrier family 22 member 11","graph1":"Undisclosed","graph2":"Phase I","graph3":"TrippBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"TrippBio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TrippBio \/ Undisclosed"},{"orgOrder":0,"company":"TrippBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Probenecid","moa":"Solute carrier family 22 member 6 | Solute carrier family 22 member 8 | Solute carrier family 22 member 11","graph1":"Undisclosed","graph2":"Phase I","graph3":"TrippBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"TrippBio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TrippBio \/ Undisclosed"},{"orgOrder":0,"company":"TrippBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Probenecid","moa":"Solute carrier family 22 member 6 | Solute carrier family 22 member 8 | Solute carrier family 22 member 11","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TrippBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TrippBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TrippBio \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by TrippBio

    Menu

    TrippBio

    EVENTS

    • Webinars & Exhibitions

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            TrippBio

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            TrippBio

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Probenecid

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Evaluation of the Effect of Food on the PK of a Novel PanCytoVirâ„¢ Suspension (100mg/ml), in Healthy, ...

                            Details : Probenecid is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 06, 2023

                            Lead Product(s) : Probenecid

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            TrippBio

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            TrippBio

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Probenecid

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Relative Bioavailability Study With a Novel PanCytoVirâ„¢ Oral Suspension (100 mg/ml)

                            Details : Probenecid is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 06, 2023

                            Lead Product(s) : Probenecid

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            TrippBio

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            TrippBio

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Probenecid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Efficacy of PanCytoVirâ„¢ for the Treatment of Non-Hospitalized Patients With COVI...

                            Details : PanCytoVir (Probenecid) is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.

                            Product Name : PanCytoVir

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 05, 2022

                            Lead Product(s) : Probenecid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            TrippBio

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            TrippBio

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TD213

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TrippBio Reports Results from Investigator-Initiated Clinical Trial of TD213 for the Treatment of Mild to Mode...

                            Details : TrippBio is developing a patent-pending repurposed FDA-approved drug called TD213. After 14 days, 90% of enrolled patients receiving TD213 had cleared the virus.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 16, 2020

                            Lead Product(s) : TD213

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            TrippBio

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            TrippBio

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TD213

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TrippBio Completes Enrollment in a Proof of Concept Trial Evaluating the Efficacy of TD213 in Treating Patient...

                            Details : TD213 works by blocking the SARS-CoV-2 virus' replication and the associated acute inflammatory response to the infection.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 22, 2020

                            Lead Product(s) : TD213

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth